In November 2005, scientists gathered at Times Square in New York City announced the
exciting news of the successful development of the world’s first cervical cancer vaccine.
The cervical cancer vaccine, which is able to protect unexposed women against the
infection with four HPV strains responsible for 70% of cervical cancers, was approved
for human use by the US Federal Drug Administration (FDA) and a number of other countries.
The Times magazine reported the development of the cervical cancer vaccine as one
of the world’s top ten scientific and technological achievements of 2006. In August
2006, the first dose of the vaccine was administered by Professor Ian Frazer in the
presence of Anna Bligh, the Premier of Queensland. Anna Bligh said “Today we are making
medical history. It is a great moment for science in this country.” Professor Frazer
said that this historic breakthrough could not have been achieved without the contribution
of Dr. Jian Zhou (Fig. 1). Sadly, Dr. Zhou, the great inventor of the vaccine, passed
away in 1999 and was unable to see the benefits brought by the vaccine.
Figure 1
Statue photo of Dr. Jian Zhou on the campus of Wenzhou Medical University
Dr. Zhou was born in 1957 in Hangzhou, Zhejiang Province, China. At the time of his
birth, his father was already 50 years old and the birth of a boy brought the family
hope and joy. As a child, Dr. Zhou was active and playful and was often asked to leave
his kindergarten classroom because he was busy in doing and playing by himself (Fig. 2).
However, the punishment did not seem to affect the young Dr. Zhou and he was often
seen having a good time playing by himself outside of the classroom. Even as a child,
he seemed to have inexhaustible energy and this energy, an important factor that contributed
to his later success, stayed with him all of his life.
Figure 2
Dr. Jian Zhou’s childhood photo
Dr. Zhou spent his childhood in Hangzhou. After graduating from high school, he was
sent to work in a rural village as a consequence of the “Cultural Revolution” in China.
There was no school to attend. During his time working in the village, Dr. Zhou gained
profound empathy for the hardships experienced by farmers. After working on farms
for a year, he returned to Hangzhou as a temporary worker at the “June-One Knitting
Factory”. There, he pulled carts and carried packages weighing more than 50 kilograms
for a measly eighty cents a day. Although the work was extremely hard, Dr. Zhou never
lost his spirit. Later, Dr. Zhou worked as a welding apprentice at a radio factory.
Because of his youth and lanky build, a number of team leaders at the factory were
reluctant to accept him as their apprentice. However, one team leader noticed that
he was very smart, more thoughtful than others and had skilful hands—he was able to
grasp the welding technology and produce high quality products quickly. This team
leader took the young Dr. Zhou on and relied on him as a core team member until he
left the factory to attend university. Dr. Zhou’s experiences of working on farms
and in factories cultivated his ability to endure hardships and his dedication to
the development of science.
In 1977, Dr. Zhou was admitted to study at the Department of Medicine at Wenzhou Medical
University where he obtained his Bachelor of Medicine degree. After graduation, he
went on to study at the Zhejiang Medical University and obtained a Master’s degree
in Medical Sciences. It was at the Zhejiang Medical University that Dr. Zhou began
to study the human papillomavirus and developed his interest in the field of human
pathology. In 1985, Dr. Zhou began his PhD studies in human pathology at the Henan
Medical University where he continued his research in human papillomavirus. During
that time, he also attended the Institute of Virology, Chinese Academy of Preventive
Medicine and studied molecular virology and molecular cloning technology. During his
Master’s degree and PhD studies, Dr. Zhou discovered that the development of esophageal
cancer is associated with human papillomavirus infections. He received a national
award in China for this discovery. In 1988, after he had obtained his PhD degree,
Dr. Zhou undertook his first postdoctoral study at Beijing Medical University. During
this period, he used vaccinia virus as a vector to express a specific protein in vitro,
thereby laying the technological foundation for his later invention. In the same year,
he was invited to work at the Tumor Virus Laboratory, in the Department of Pathology
of Cambridge University to continue molecular biology research in the human papillomavirus
under the guidance of Professor Lionel Crawford (Fig. 3). Dr. Zhou’s hard work, diligence
and innovation allowed him to develop a clear understanding of the state of the research
and the developmental direction for human papillomavirus research. He was soon publishing
influential papers in journals such as the Journal of General Virology, Virology,
Journal of Virology and other well-known international journals.
Figure 3
Dr. Jian Zhou (left) at the Tumor Virus Laboratory of Cambridge University
Dr. Zhou first met Professor Frazer, an immunologist from the University of Queensland,
at Cambridge. Impressed by Dr. Zhou’s creative research ideas and bonded by mutual
respect, Professor Frazer convinced Dr. Zhou to join him in Australia to pursue their
common interest in human papillomavirus research. In 1990, Dr. Zhou joined Professor
Frazer at the University of Queensland, Australia, starting the most important chapter
of Dr. Zhou’s research career.
After multiple experiments, Dr. Zhou successfully used vaccinia virus as a carrier
to express papillomavirus L1 and L2 capsid proteins in mammalian cells in vitro using
recombinant DNA technology. The expressed capsid protein can be self-assembled into
virus-like particles. In the same year, Dr. Zhou and Professor Frazer published these
results in the Virology Journal (Zhou et al., 1991a). In June 1991, the University
of Queensland applied for a provisional patent for the invention. In July of that
year, Dr. Zhou and Professor Frazer reported their results at the International Conference
of Human Papillomavirus in Seattle in the United States. This achievement was considered
a major breakthrough in human medical history. Australian medical company, CSL and
later Merck company, USA conducted large-scale animal and human clinical trials which
ultimately verified the effect of human papillomavirus-like particles on the prevention
of cervical cancer.
Dr. Zhou was an incredibly talented scientist. His contributions to papillomavirus
and cancer biology research were exceptional. During his first four years at the Centre
for Immunology and Cancer Research (later renamed The Diamantina Institute for Cancer,
Immunology and Metabolic Medicine) at the University of Queensland, he published 11
first-author scientific papers in leading virology journals. This is an incredible
achievement for any scientist involved in biomedical research. During his research
career, Dr. Zhou made a number of world-renowned inventions and obtained twelve invention
patents within eight years. One of these involved the discovery that the minor papillomavirus
capsid protein L2 plays a crucial role in DNA binding and capsidification, revealing
the importance of this capsid protein in the HPV life cycle (Zhou et al., 1991b).
Dr. Zhou also found that L1 protein C-terminus does not affect the formation of capsids.
This discovery led to the use of a chimeric capsid consisting of the C-terminal truncated
L1 protein, and other T-cell epitopes of the early proteins of the virus, to produce
both prophylactic and therapeutic vaccines. Another very novel study was genetic code
(gene codon) optimization. In this study, he found that the HPV L1 and L2 capsid genes
could not be expressed in most mammalian cells, but it can be expressed in yeast because
the transfer ribonucleic acid (tRNA) in mammalian cells limits the expression of the
capsid genes (Zhou et al., 1999). Dr. Zhou discovered that a capsid gene using the
mammalian rare codon effectively expresses capsid protein in the infected terminal
differentiation epithelium. Codon optimization and change could be used to improve
significantly the efficiency of protein expression and improve the immunogenicity
of the vaccine and opened up a new gene therapy technology (Zhou et al., 1999).
Dr. Zhou received his MD from the University of Queensland in 1994. After this he
took on an associate professorship at the Loyola University School of Medicine in
Chicago. He set up his own research group there and supervised PhD students and postdoctoral
fellows working on different research projects in medical sciences. In 1996, Dr. Zhou
returned to the University of Queensland and was appointed the principle Lions Research
fellow and the Head of the Papillomavirus Structural Protein Laboratory at the Center
for Cancer and Immunology Research (Fig. 4). In 1998, Dr. Zhou was awarded with three
research grants by the Australian National Medical and Health Research Council, a
grant by the American National Institute of Health, a grant by the American Cancer
Foundation, two grants by the Cancer Council Queensland, and received funding for
several other research projects from other resources as well as royalties from his
patents. In that year, Dr. Zhou was the well-funded researcher receiving the largest
amount of research funding in the history of the University of Queensland.
Figure 4
Dr. Jian Zhou (1st from left in the front row) at the Center for Cancer and Immunology
Research of The University of Queensland
Dr. Zhou was always proud of being a graduate of the Wenzhou Medical University and
was always concerned with the development of teaching and scientific research at his
alma mater. He travelled to Wenzhou Medical University to give lectures and guide
scientific research and was selfless in spending his personal time and money inviting
scholars from his alma mater to further their studies overseas (Fig. 5). One such
example occurred in 1996 when Dr. Zhou was based in Chicago. When he found out that
a scholar from his alma mater was studying in Boston, he immediately sent that person
return flight tickets between Boston and Chicago so that they could get together to
discuss how to support and carry out scientific research at the Wenzhou Medical University.
Later, after Dr. Zhou joined the University of Queensland, he established a joint
program between the Wenzhou Medical University and the University of Queensland to
further scientific research collaboration and facilitate the exchange of medical students
to accelerate the development of his alma mater. His family established the “Dr. Jian
Zhou Foundation” to provide scholarships to medical students from Wenzhou Medical
University, Dr. Zhou’s alma mater, to undertake PhD studies outside of China to train
as medical research scientists. Dr. Zhou made a significant contribution to the development
of Wenzhou Medical University as a well-known university in China and the world now.
Figure 5
Dr. Jian Zhou (5th from the left) and Professor Ian Frazer (5th from right) at the
first affiliation hospital of Wenzhou Medical University
Dr. Zhou’s outstanding contributions to science and humanity have been recognised
and commemorated. The Diamantina Institute for Cancer, Immunology and Metabolic Medicine
of the University of Queensland established the annual Jian Zhou Memorial Oration
at which world renowned scientists give lectures to commemorate Dr. Zhou. The Diamantina
Institute has also named one of its conference rooms the Jian Zhou room. Since 2000,
the annual international HPV Conference has held a number of memorials for Dr. Zhou.
The Asian-Oceania Research Organization on Genital Infection and Neoplasia (AOGIN)
in 2006 established the AOGIN Dr. Jian Zhou award as one of the three awards for best
oral presentation. In 2006, the Queensland Government established the “Dr. Jian Zhou
Smart State Fellowships Program”. The Queensland Government, the Australian Chinese
Society and Australia-China Friendship Society organized the “Dr. Zhou Jian Memorial”
and published a book entitled “Dr. Jian Zhou’s Brilliant Mind — The Inventor of Cervical
Cancer Vaccine”《英才济苍生》(Fig. 6). Lastly, the vaccine against human papillomavirus (HPV)
jointly invented by Dr. Zhou and Professor Frazer won the European Inventor Patent
award in 2015.
Figure 6
Cover photo of Dr. Jian Zhou memorial book